Liver Disease Clinical Trials in Los Angeles

Showing 61-80 of 88 trials

Ketogenic Diet in Non-alcoholic Fatty Liver Disease

NCT03784716

The purpose of this randomized trial is to examine the effects of a ketogenic diet on non-alcoholic fatty liver disease (NAFLD). Twenty-four participants with NAFLD will be randomized to receive a ketogenic meal plan or control (standard weight loss meal plan). Participants will be followed up to 28 days after initiation of the diet intervention.

Fatty Liver, NonalcoholicLiver Diseases

Marc Goodman24 participantsStarted Mar 2019

Los Angeles, California, United States

COMPLETED< 1 mile

Liver Fat and Iron Quantification MRI

NCT03162302

The objective of this study is to develop and evaluate novel magnetic resonance imaging (MRI) protocols for studying the structure and function of the human body using 1.5 Tesla and 3.0 Tesla MRI scanners with or without the use of an MRI contrast agent.

Liver Diseases

University of California, Los Angeles62 participantsStarted May 2017

Los Angeles, California, United States

COMPLETEDPhase 2< 1 mile

A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC-0602K in Patients With NASH

NCT02784444

This is a randomized, double-blinded study of three doses of MSDC-0602K or placebo given orally once daily to subjects with biopsy proven NASH with fibrosis and no cirrhosis.

Non-alcoholic Fatty Liver DiseaseNon-alcoholic SteatohepatitisNASH - Nonalcoholic Steatohepatitis

Cirius Therapeutics, Inc.392 participantsStarted Sep 2016

Chandler, Arizona, United States • Tucson, Arizona, United States • Chula Vista, California, United States +40 more locations

Ketogenic Diet in Non-alcoholic Fatty Liver Disease

Liver Fat and Iron Quantification MRI

A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC-0602K in Patients With NASH

Liver Disease Trials in Other Cities

Different Doses of BI 1467335 Compared to Placebo in Patients With Clinical Evidence of NASH

Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis

Emricasan, a Caspase Inhibitor, for Treatment of Subjects With Decompensated NASH Cirrhosis

A Study of HTD1801 in Adults With Nonalcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM)

The Safety/Efficacy of Rifaximin With/Without Lactulose in Participants With A History of Recurrent Hepatic Encephalopathy

The Effect Of NS-0200 Versus Placebo On Hepatic Fat Content In Patients With Non Alcoholic Fatty Liver Disease

Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Participants With Nonalcoholic Steatohepatitis

Nonalcoholic Fatty Liver Disease (NAFLD) Adult Database 2

Phase 2 Study to Evaluate LUM001 in Combination With Ursodeoxycholic Acid in Patients With Primary Biliary Cirrhosis

An Open-label Study to Evaluate the Long-term Safety and Tolerability of LUM001 in Patients With Primary Biliary Cirrhosis

Losartan for the Treatment of Pediatric NAFLD

Cysteamine Bitartrate Delayed-Release for the Treatment of NAFLD in Children

Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis

Benign Liver Optimal Core Study (Tissue Acquisition Comparison in Benign Liver Disease)

A (M)Ulti-center, Prospective, (O)Pen Label, Uncontrolled Feasibility (S)Tudy to Assess the Safety and Effectiveness of an Automatic Low Flow (A)Scites (Alfa) Pump (I)n Patients With (C)Irrhosis and Refractory or Recurrent Ascites

The Patient-Reported Outcomes Project of HCV-TARGET

Study of INT-747 as Monotherapy in Participants With Primary Biliary Cirrhosis (PBC)

Other Conditions in Los Angeles